- New Research Demonstrates Multifactorial Beneficial Effects of VASCEPA/VAZKEPA on Coronary Physiology and Plaque Progression - Data Further Advances Understanding of VASCEPA/VAZKEPA Potential Mechanism
— New Research Demonstrates Multifactorial Beneficial Effects of VASCEPA/VAZKEPA on Coronary Physiology and Plaque Progression — Data Further Advances Understanding of VASCEPA/VAZKEPA. | May 12, 2023
Stable Revenue and Cash Position Due to Performance of U.S. Business and Savings from Operational Initiatives Early Progress in Launch of VAZKEPA® (icosapent ethyl) in England & Wales; Pricing
New Amarin Board Believes the Company Will Thrive with Proper Stewardship New Amarin Directors are Working with Urgency to Address Issues at Amarin DUBLIN, Ireland and BRIDGEWATER, N.J., March
Investegate announcements from Amarin Corporation plc, Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl)